We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme (thrombEVAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01809015
Recruitment Status : Active, not recruiting
First Posted : March 12, 2013
Last Update Posted : May 15, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:

Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine. Increasing life-expectancy, the demographic change and novel oral anticoagulants lead to an increasing complexity of medical therapy. However, data on quality and management of VKA therapy with phenprocoumon in current medical care are limited. Our aim was to investigate the quality of OAC with VKA in current health care and to evaluate the potential for improvements.

The investigator-initiated thrombEVAL study program comprises two cohorts of patients treated with vitamin K antagonists for oral anticoagulation therapy in real-life settings: a multicentre cohort of patients in regular medical care and a multi-local, single centre cohort of patients in a telemedicine-based coagulation service. The study program is expected to enrol a total number of approximately 2,000 to 2,500 patients. Both cohorts build on a detailed clinical assessment of participants and anticoagulation therapy at study enrolment. Subsequently active and passive follow-up investigations are carried out to document and validate complications of the treatment. Primary short-term outcome is the distribution of time in therapeutic range; the primary long-term outcome comprises the composite of stroke, systemic embolism, myocardial infarction, major and clinically-relevant bleeding and death.

Condition or disease
PHENPROCOUMON/VITAMIN K [VA Drug Interaction] Atrial Fibrillation Venous Thromboembolism

Study Design

Study Type : Observational
Estimated Enrollment : 2500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Study Programme for the Evaluation of Oral Anticoagulation Therapy With Vitamin K Antagonists
Study Start Date : January 2011
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin K
Drug Information available for: Menadione
U.S. FDA Resources

Groups and Cohorts

Cohort A: Regular medical care
Patients treated with vitamin K antagonists in regular medical care system
Cohort B: Coagulation service
Patients with oral anticoagulation therapy in a telemedicine-based coagulation service

Outcome Measures

Primary Outcome Measures :
  1. Time in therapeutic range [ Time Frame: Assessment during Year 1 after study enrolment ]
    Time in therapeutic range for the International Normalized Ratio as measured by linear interpolation method

  2. Hospitalisation [ Time Frame: Assessment at year 1 and 2 after study enrolment ]
    Any Hospitalisation

  3. Net clinical benefit [ Time Frame: Assessment at year 1 and 2 ]
    Composite of stroke, systemic embolism, pulmonary embolism, myocardial infarction, major and clinically relevant, non-major bleeding and death

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

In cohort A, patients of regular medical care are enrolled in the area of Rhineland-Palatinate, Germany. Treatment and management of oral anticoagulation therapy with vitamin K antagonists is performed within primary (ambulatory) care system.

In cohort B, patients are treated with oral anticoagulation in a specialized telemedicine-based coagulation service in the area of Rhinehesse, Germany.


Inclusion Criteria

  1. Age ≥ 18 years of age at study inclusion
  2. Written informed consent by patient or legal guardian, if appointed
  3. Cohort A: Pretreatment with oral anticoagulation therapy with vitamin K antagonists (VKA) for at least 4 months in regular medical care including patients with self-management of oral anticoagulation therapy
  4. Cohort B: Indication for oral anticoagulation therapy with VKA for at least 3 months (both drug-naive and -experienced patients) at enrolment including patients with self-management of oral anticoagulation therapy.

Exclusion Criteria

  1. Contraindication to VKA treatment, e.g. pregnancy or known hypersensitivity
  2. Participation in other clinical trial
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01809015

University Medical Center of the Johannes Gutenberg University Mainz
Mainz, Rhineland-Palatinate, Germany, 55131
Sponsors and Collaborators
Johannes Gutenberg University Mainz
Ministry of Health, Rhineland-Palatinate, Germany
Ministry of Economics, Rhineland-Palatinate, Germany
German Federal Ministry of Education and Research
Boehringer Ingelheim
Daiichi Sankyo Europe, GmbH
IMO Institut GmbH
PortaVita BV
The German Heart Foundation
Principal Investigator: Philipp S Wild, MD, MSc University Medical Center of Johannes Gutenberg-University Mainz, Germany
Principal Investigator: Thomas F Munzel, MD University Medical Center of Johannes Gutenberg-University Mainz, Germany
More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Philipp Wild, MD, MSc, Univ.-Prof. Dr. med. Philipp Wild, MSc, Johannes Gutenberg University Mainz
ClinicalTrials.gov Identifier: NCT01809015     History of Changes
Other Study ID Numbers: UMCM-2010EPI01
First Posted: March 12, 2013    Key Record Dates
Last Update Posted: May 15, 2014
Last Verified: May 2014

Keywords provided by Philipp Wild, MD, MSc, Johannes Gutenberg University Mainz:
Oral Anticoagulation
Regular Medical Care
Coagulation Service
Vitamin-K Antagonists
Quality of therapy
Atrial fibrillation
Venous thromboembolism
Bypass surgery
Prosthetic heart valve

Additional relevant MeSH terms:
Atrial Fibrillation
Venous Thromboembolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Vitamin K
Growth Substances
Physiological Effects of Drugs
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action